P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML - PubMed
3 days ago
- #Leukemia Stem Cells
- #AML
- #Epigenetic Therapy
- Combination therapy using p300/CBP inhibitor inobrodib with venetoclax and gilteritinib effectively targets leukemia stem cells in preclinical DNMT3A/FLT3-mutant AML models.
- This triplet therapy disrupts pro-oncogenic survival and proliferation pathways, offering a potential curative treatment with minimal side effects compared to traditional cytotoxic chemotherapy.
- While venetoclax and gilteritinib are already used in AML, adding inobrodib enhances efficacy, highlighting its promise for targeted combination therapies in epigenetic mutant AML.